Dow Jones
39.810,94 -62,05 (-0,16%) Nasdaq
16.847,61 +14,99 (+0,09%) Nikkei 225
38.617,10 -329,83 (-0,85%) EUR/USD
1,0845 -0,0014 (-0,13%) Bitcoin EUR
64.813,04 +195,27 (+0,30%) CMC Crypto 200
1.520,18 -6,23 (-0,41%)
IMTX May 2024 7.500 put
| Chiusura precedente | 0,0500 |
| Aperto | 0,0500 |
| Denaro | 0,0000 |
| Domanda | 0,7500 |
| Prezzo d'esercizio | 7,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,0500 - 0,0600 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 888 |
GlobeNewswireImmatics Announces Second Quarter 2023 Financial Results and Business Update
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023Bristol Myers Squibb exercised first opt-in into
- GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumorsFirst clinical data expected in 2024 Tuebingen, Germany and Houston, Texas, August 10, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the disc
- GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461. Additionally, Bristol Myers Squ
